Presence and type of low density lipoprotein receptor (LDLR) mutation influences the lipid profile and response to lipid-lowering therapy in Brazilian patients with heterozygous familial hypercholesterolemia

Atherosclerosis

Volumn 233, Issue 1, 2014, Pages 206-210

  Santos, Paulo Caleb Junior Lima ^a   Morgan, Aline Cruz ^a   Jannes, Cintia Elin ^a   Turolla, Luciana ^a   Krieger, Jose Eduardo ^a   Santos, Raul D ^a   Pereira, Alexandre Costa ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Familial hypercholesterolemia; LDLR gene; Lipid lowering therapy; Type of mutation

Indexed keywords

FAMILIAL HYPERCHOLESTEROLEMIA; LDLR GENE; LIPID-LOWERING THERAPY; TYPE OF MUTATION;

ADULT; AGED; AZETIDINES; BRAZIL; CHOLESTEROL, LDL; FEMALE; HEPTANOIC ACIDS; HETEROZYGOTE; HUMANS; HYPERLIPOPROTEINEMIA TYPE II; LIPIDS; MALE; MIDDLE AGED; PYRROLES; RECEPTORS, LDL;

EID: 84893847744     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2013.12.028     Document Type: Article

References (33)

1. Huijgen R., Vissers M.N., Defesche J.C., Lansberg P.J., Kastelein J.J., Hutten B.A. Familial hypercholesterolemia: current treatment and advances in management. Expert Rev Cardiovasc Ther 2008, 6:567-581.
2. Pijlman A.H., Huijgen R., Verhagen S.N., et al. Evaluation of cholesterol lowering treatment of patients with familial hypercholesterolemia: a large cross-sectional study in The Netherlands. Atherosclerosis 2010, 209:189-194.
3. Schaefer J.R., Kurt B., Sattler A., Klaus G., Soufi M. Pharmacogenetic aspects in familial hypercholesterolemia with the special focus on FHMarburg (FH p.W556R). Clin Res Cardiol Suppl 2012, 7:2-6.
4. Choumerianou D.M., Dedoussis G.V. Familial hypercholesterolemia and response to statin therapy according to LDLR genetic background. Clin Chem Lab Med 2005, 43:793-801.
5. Hobbs H.H., Russell D.W., Brown M.S., Goldstein J.L. The LDL receptor locus in familial hypercholesterolemia: mutational analysis of a membrane protein. Annu Rev Genet 1990, 24:133-170.
6. Miltiadous G., Xenophontos S., Bairaktari E., Ganotakis M., Cariolou M., Elisaf M. Genetic and environmental factors affecting the response to statin therapy in patients with molecularly defined familial hypercholesterolaemia. Pharmacogenet Genomics 2005, 15:219-225.
7. Baigent C., Keech A., Kearney P.M., et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005, 366:1267-1278.
8. Ghatak A., Faheem O., Thompson P.D. The genetics of statin-induced myopathy. Atherosclerosis 2010, 210:337-343.
9. Santos R.D., Gagliardi A.C., Xavier H.T., et al. Arq Bras Cardiol 2013, 99:1-28.
10. Nordestgaard B.G., Chapman M.J., Humphries S.E., et al. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European atherosclerosis society. Eur Heart J 2013, Aug 15, [Epub ahead of print].
11. Torres A.L., Moorjani S., Vohl M.C., et al. Heterozygous familial hypercholesterolemia in children: low-density lipoprotein receptor mutational analysis and variation in the expression of plasma lipoprotein-lipid concentrations. Atherosclerosis 1996, 126:163-171.
12. Sun X.M., Patel D.D., Knight B.L., Soutar A.K. Influence of genotype at the low density lipoprotein (LDL) receptor gene locus on the clinical phenotype and response to lipid-lowering drug therapy in heterozygous familial hypercholesterolaemia. The Familial Hypercholesterolaemia Regression Study Group. Atherosclerosis 1998, 136:175-185.
13. Sijbrands E.J., Lombardi M.P., Westendorp R.G., et al. Similar response to simvastatin in patients heterozygous for familial hypercholesterolemia with mRNA negative and mRNA positive mutations. Atherosclerosis 1998, 136:247-254.
14. Jeenah M., September W., Graadt van Roggen F., de Villiers W., Seftel H., Marais D. Influence of specific mutations at the LDL-receptor gene locus on the response to simvastatin therapy in Afrikaner patients with heterozygous familial hypercholesterolaemia. Atherosclerosis 1993, 98:51-58.
15. Heath K.E., Gudnason V., Humphries S.E., Seed M. The type of mutation in the low density lipoprotein receptor gene influences the cholesterol-lowering response of the HMG-CoA reductase inhibitor simvastatin in patients with heterozygous familial hypercholesterolaemia. Atherosclerosis 1999, 143:41-54.
16. Couture P., Brun L.D., Szots F., et al. Association of specific LDL receptor gene mutations with differential plasma lipoprotein response to simvastatin in young French Canadians with heterozygous familial hypercholesterolemia. Arterioscler Thromb Vasc Biol 1998, 18:1007-1012.
17. Chaves F.J., Real J.T., Garcia-Garcia A.B., et al. Genetic diagnosis of familial hypercholesterolemia in a South European outbreed population: influence of low-density lipoprotein (LDL) receptor gene mutations on treatment response to simvastatin in total, LDL, and high-density lipoprotein cholesterol. JClin Endocrinol Metab 2001, 86:4926-4932.
18. Bertolini S., Cantafora A., Averna M., et al. Clinical expression of familial hypercholesterolemia in clusters of mutations of the LDL receptor gene that cause a receptor-defective or receptor-negative phenotype. Arterioscler Thromb Vasc Biol 2000, 20:E41-E52.
19. Santos P.C., Gagliardi A.C., Miname M.H., et al. SLCO1B1 haplotypes are not associated with atorvastatin-induced myalgia in Brazilian patients with familial hypercholesterolemia. Eur J Clin Pharmacol 2012 Mar, 68(3):273-279.
20. Williams R.R., Hunt S.C., Schumacher M.C., et al. Diagnosing heterozygous familial hypercholesterolemia using new practical criteria validated by molecular genetics. Am J Cardiol 1993, 72:171-176.
21. Link E., Parish S., Armitage J., et al. SLCO1B1 variants and statin-induced myopathy-a genomewide study. NEngl J Med 2008, 359:789-799.
22. Alonso R., Mata N., Castillo S., et al. Cardiovascular disease in familial hypercholesterolaemia: influence of low-density lipoprotein receptor mutation type and classic risk factors. Atherosclerosis 2008, 200:315-321.
23. Bertolini S., Cassanelli S., Garuti R., et al. Analysis of LDL receptor gene mutations in Italian patients with homozygous familial hypercholesterolemia. Arterioscler Thromb Vasc Biol 1999, 19:408-418.
24. Hobbs H.H., Brown M.S., Goldstein J.L. Molecular genetics of the LDL receptor gene in familial hypercholesterolemia. Hum Mutat 1992, 1:445-466.
25. Leigh S.E., Foster A.H., Whittall R.A., Hubbart C.S., Humphries S.E. Update and analysis of the University College London low density lipoprotein receptor familial hypercholesterolemia database. Ann Hum Genet 2008, 72:485-498.
26. Mozas P., Castillo S., Tejedor D., et al. Molecular characterization of familial hypercholesterolemia in Spain: identification of 39 novel and 77 recurrent mutations in LDLR. Hum Mutat 2004, 24:187.
27. Leitersdorf E., Eisenberg S., Eliav O., et al. Genetic determinants of responsiveness to the HMG-CoA reductase inhibitor fluvastatin in patients with molecularly defined heterozygous familial hypercholesterolemia. Circulation 1993, 87:III35-III44.
28. Mata N., Alonso R., Badimon L., et al. Clinical characteristics and evaluation of LDL-cholesterol treatment of the Spanish Familial Hypercholesterolemia Longitudinal Cohort Study (SAFEHEART). Lipids Health Dis 2011, 10:94.
29. Vohl M.C., Szots F., Lelievre M., et al. Influence of LDL receptor gene mutation and apo E polymorphism on lipoprotein response to simvastatin treatment among adolescents with heterozygous familial hypercholesterolemia. Atherosclerosis 2002, 160:361-368.
30. Alvim R.O., Freitas S.R., Ferreira N.E., et al. APOE polymorphism is associated with lipid profile, but not with arterial stiffness in the general population. Lipids Health Dis 2010, 9:128.
31. Niemi M., Pasanen M.K., Neuvonen P.J. Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake. Pharmacol Rev 2011, 63:157-181.
32. Santos P.C., Alvim Rde O., Ferreira N.E., et al. Ethnicity and arterial stiffness in Brazil. Am J Hypertens 2011, 24:278-284.
33. Santos P.C., Soares R.A., Nascimento R.M., et al. SLCO1B1 rs4149056 polymorphism associated with statin-induced myopathy is differently distributed according to ethnicity in the Brazilian general population: Amerindians as a high risk ethnic group. BMC Med Genet 2011, 12:136.